TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease
I'm PortAI, I can summarize articles.
TransCode Therapeutics Inc. has completed its Phase 1a trial for TTX-MC138, an inhibitor of microRNA-10b, in metastatic disease. The trial met safety endpoints and established a recommended Phase 2 dose, with no significant safety events. Preliminary data showed stable disease in 44% of patients. The company plans to advance to Phase 2a trials to further assess efficacy in selected metastatic diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments